The present invention relates to an analytical method that includes providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms, and providing a probe selected from the group consisting of coumarin-derived Michael acceptors, dinitrofluoroarenes and analogs thereof, arylsulfonyl chlorides and analogs thereof, arylchlorophosphines and analogs thereof, aryl halophosphites, and halodiazaphosphites. The sample is contacted with the probe under conditions to permit covalent binding of the probe to the analyte, if present in the sample; and, based on any binding that occurs, the absolute configuration of the analyte in the sample, and/or the concentration of the analyte in the sample, and/or the enantiomeric composition of the analyte in the sample is/are determined. The probe may be a coumarin-derived Michael acceptor, a di nitrofluoroarene or analog thereof, an arylsulfonyl chloride or analog thereof, an arylchlorophosphine or analog thereof, an aryl halophosphite, or a halodiazaphosphite.

The disclosed technology relates to a secondary battery electrolyte and a lithium secondary battery including the same. The secondary battery electrolyte of the disclosed technology includes a cyclophosphate compound as an additive, such that the secondary battery electrolyte has excellent flame retardancy while improving charge and discharge efficiency, lifespan characteristics, high-temperature characteristics, and high-temperature storage stability of a lithium secondary battery including the same.

Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.

The present disclosure relates to compounds of Formula (I) or (II): (Formulae (I), (II)), and pharmaceutically acceptable salts or solvates thereof. The present disclosure also relates to pharmaceutical compositions comprising the compounds and therapeutic and diagnostic uses of the compounds and pharmaceutical compositions.

##STR00001##

Diphosphites having an open and a closed 2,4-methylated outer unit and use thereof in hydroformylation.

Disclosed herein are compounds of formulas (I) and (II), Wherein R.sub.1, R.sub.2, R.sub.3 and (1) are as described herein. Methods of making compounds of formulas (I) and (II), curable compositions containing them and cured compositions containing them are also described. The compounds of formulas (I) and II are curing agents, fire retardants or both. ##STR00001##

A method for preparing a bisphenol phosphate hydroxyl aluminum salt nucleating agent is provided, which adopts organic aluminum alcoholate as raw materials to prepare bisphenol phosphate hydroxyl aluminum salt. In prior art, a neutralization reaction of bisphenol phosphate and sodium hydroxide is firstly performed, so as to prepare bisphenol phosphate sodium salt; then a double decomposition reaction of sodium salt and inorganic aluminum salt is performed to prepare the bisphenol phosphate hydroxyl aluminum salt. The present invention combines the two-step reaction in prior art into the one-step reaction of phosphate and organic aluminum alcoholate for synthesizing the bisphenol phosphate hydroxyl aluminum salt, thereby simplifying the production process, improving the production efficiency, shortening the reaction time, and improving the product quality. Moreover, during the production process of the preparation method provided by the present invention, no brine waste is generated, so that the production process is environment-friendly.

Provided are novel prodrugs of treprostinil, as well as methods of making and methods of using these prodrugs.

The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.

The invention relates to compositions of nicotinamide mononucleotide derivatives and their methods of use. The invention also relates to methods of preparing nicotinamide mononucleotide derivatives. The invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinamide mononucleotide derivative. The invention relates to methods of using nicotinamide mononucleotide derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for treating diseases and improving cell and tissue survival.